Tag: biologics

Displaying 1 - 20 of 20 results.

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Bristol-Myers Squibb Company’s proposed $74 billion acquisition of Celgene Corporation would violate federal antitrust law.
Pharmaceutical and biologic manufacturers Bristol-Myers Squibb Company, or BMS, and Celgene Corporation have agreed to divest Celgene’s Otezla, the most popular oral treatment in the United States for moderate-to-severe psoriasis, for $13.4 billion. This divestiture would settle Federal Trade...
WHAT:The Federal Trade Commission will host a workshop, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics”. Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr.
The number of reverse-payment patent settlements entered into by pharmaceutical companies in fiscal year 2015 declined from fiscal year 2014, marking a second annual decrease in such settlements, according to a new FTC staff report.
The Federal Trade Commission has announced an agenda for its upcoming workshop on competition issues related to prescription drug markets. The workshop, titled “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics,” will take place on November 8, 2017 at the FTC’s...
The Federal Trade Commission will hold a workshop on November 8, 2017 entitled, “Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics.” Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and Drug Commissioner Dr. Scott Gottlieb will give the keynote addresses.
A few minutes ago, FTC Chairwoman Edith Ramirez delivered opening remarks to kick off today’s FTC workshop exploring emerging issues affecting competition and patient access to biologic medicines. You can view a live webcast of the workshop on the FTC’s website, or follow live tweets...
The Federal Trade Commission is hosting a workshop on competition issues surrounding biologics and follow-on biologic medicines on Feb. 4, 2014, in Washington, DC, and invites live webcast viewers to submit questions to moderators online.
Tomorrow, the FTC will host a workshop to explore emerging issues affecting competition and consumer access to biologic medicines.
The Federal Trade Commission today issued the final agenda for its one-day public workshop on competition and follow-on biologics, which will be held on February 4 at its Conference Center located at 601 New Jersey Ave., NW, in Washington, DC.
The Federal Trade Commission announced its one-day public workshop on competition and follow-on biologics has been rescheduled for Feb. 4, 2014. The workshop will be held at the FTC’s Conference Center located at 601 New Jersey Ave., NW, in Washington, and will examine competition issues...
Due to inclement weather and the closure of the federal government for today, the Federal Trade Commission has postponed until further notice its one-day public workshop on Follow-On Biologics: Impact of Recent Legislative and Regulatory Naming Proposals on Competition.
When faced with a major illness, patients usually want the best medicine available, regardless of cost. In some cases, next-generation “biologic” medicines may be the best treatments available. Unfortunately, these critical treatments can be very expensive. For example, Herceptin,...
The Federal Trade Commission has announced the agenda for the upcoming public roundtable on “Follow-on Biologics: Impact of Recent Legislative and Regulatory Naming Proposals on Competition.” The workshop will be held in the FTC Conference Center at 601 New Jersey Ave., N.W., in Wa
The Federal Trade Commission held a workshop to explore competition issues involving biologic medicines and follow-on biologics. As described in the Federal Register Notice, the workshop focused on a few key issues, inter alia:
The Federal Trade Commission will host a one-day public workshop on December 10, 2013, at its headquarters in Washington, DC, to examine competition issues surrounding biologic and follow-on biologic medications.
Testifying today on behalf of the Federal Trade Commission before the Subcommittee on Health of the U.S. House of Representatives Energy and Commerce Committee, Commissioner Pamela Jones Harbour presented the findings and recommendations of the FTC’s new Report, “Follow-on Biologic Drug Competition...
The Federal Trade Commission today released a report entitled “Follow-on Biologic Drug Competition”which examines whether the price of biologic drugs – products manufactured using living tissues and microorganisms – could be reduced by competition from so-called “follow-on biologics” (FOBs). FOBs...
The Federal Trade Commission has announced the agenda for the upcoming public roundtable on “Follow-on Biologic Drugs: Framework for Competition and Continued Innovation.” The roundtable will be held in Room 432 at FTC Headquarters in Washington, DC, on November 21, 2008. FTC Commissioner Pamela...